tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Retrognathia D063173 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Scorpion Stings D065008 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Reggiani P et al. Conversion to rescue therapy with FK 506: data from eight liver transplant patients. 1994 Transplant. Proc. pmid:7527982
Lemmens HP et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. 1994 Transplant. Proc. pmid:7527983
Mueller AR et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. 1994 Transplant. Proc. pmid:7527984
Langrehr JM et al. Mucosal recipient-type mononuclear repopulation and low-grade chronic rejection occur simultaneously in indefinitely surviving recipients of small bowel allografts. 1994 Transpl. Int. pmid:7513999
Leach KL et al. A soluble binding assay for measuring 3H-FK506 binding to the hsp56 immunophilin. 1994 J Immunoassay pmid:7530727
Genestier L et al. Cyclosporin A and FK506 inhibit activation-induced cell death in the murine WEHI-231 B cell line. 1994 Cell. Immunol. pmid:7514101
Rao US and Scarborough GA Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. 1994 Mol. Pharmacol. pmid:7514263
Lieberman DN and Mody I Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. 1994 Nature pmid:7514273
Igarashi T et al. Central nervous system toxicity related to FK506 in patients with Behçet's disease. 1994 Ann. Rheum. Dis. pmid:7517134
Eng WK et al. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. 1994 Gene pmid:7530227
Ellis D et al. Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. 1994 Pediatr. Nephrol. pmid:7517171
Petros AM and Fesik SW Nuclear magnetic resonance methods for studying protein-ligand complexes. 1994 Meth. Enzymol. pmid:7530321
Klintmalm GB FK 506: an update. 1994 Clin Transplant pmid:7517226
Dawson TM et al. The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. 1994 Neuroscience pmid:7530348
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Curley RW et al. Stereospecific assignments of glycine in proteins by stereospecific deuteration and 15N labeling. 1994 J. Biomol. NMR pmid:7517241
Nagase K et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. 1994 J. Pharm. Pharmacol. pmid:7517447
Jain A et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. 1994 Transplant. Proc. pmid:7518149
Takara T et al. Intraportal donor-specific transfusion given 24 hours before small bowel transplantation with cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7518150
Singh N et al. Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506? 1994 Dig. Dis. Sci. pmid:7506641
Kusne S et al. Infectious complications after small bowel transplantation in adults. 1994 Transplant. Proc. pmid:7518153
Lee TK et al. Bacterial translocation and the role of postoperative selective bowel decontamination in small intestinal transplantation. 1994 Transplant. Proc. pmid:7518154
Grossi P et al. Infectious complications in experimental small bowel transplantation. 1994 Transplant. Proc. pmid:7518155
Dilling MB et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. 1994 Cancer Res. pmid:7508822
Yamamoto S et al. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. 1994 J. Invest. Dermatol. pmid:7508960
Logan TM et al. Structural characterization of the FK506 binding protein unfolded in urea and guanidine hydrochloride. 1994 J. Mol. Biol. pmid:7508991
Ito T et al. Protective effects of gabexate mesilate on acute pancreatitis induced by tacrolimus (FK-506) in rats in which the pancreas was stimulated by caerulein. 1994 J. Gastroenterol. pmid:7520321
Cooper MH et al. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. 1994 Transplantation pmid:7509089
Zeniya A et al. Anti-ulcer effect of FK 506, immunosuppressive agent, in rats. 1994 J. Gastroenterol. pmid:7520322
Yamamoto S et al. Inhibition of anthralin-caused skin tumor promotion and interleukin-1 alpha production by potent immunosuppressant FK506. 1994 Cancer Lett. pmid:7520353
Dawson TM et al. Nitric oxide: cellular regulation and neuronal injury. 1994 Prog. Brain Res. pmid:7533914
Enslen H and Soderling TR Roles of calmodulin-dependent protein kinases and phosphatase in calcium-dependent transcription of immediate early genes. 1994 J. Biol. Chem. pmid:7520433
Gonschior AK et al. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). 1994 Br J Clin Pharmacol pmid:7534100
Hirano Y et al. Mechanism of FK506-induced glucose intolerance in rats. 1994 J Toxicol Sci pmid:7520947
Tacrolimus (FK506) for organ transplants. 1994 Med Lett Drugs Ther pmid:7520968
Bierer BE Biology of cyclosporin A and FK506. 1994 Prog. Clin. Biol. Res. pmid:7536944
Malyszko J et al. FK 506 affects platelet aggregation in vitro. 1994 Thromb. Res. pmid:7521072
Schreier MH Immunophilins and immunosuppression by cyclosporins and macrolide structures. 1994 Acta Derm Venereol Suppl (Stockh) pmid:7521103
Chen Y et al. A putative sirolimus (rapamycin) effector protein. 1994 Biochem. Biophys. Res. Commun. pmid:7521160
Mouzaki A and Rungger D Properties of transcription factors regulating interleukin-2 gene transcription through the NFAT binding site in untreated or drug-treated naive and memory T-helper cells. 1994 Blood pmid:7522636
Abu-Elmagd K et al. Three years clinical experience with intestinal transplantation. 1994 J. Am. Coll. Surg. pmid:7522850
Shapiro R et al. Improving results of pediatric renal transplantation. 1994 J. Am. Coll. Surg. pmid:7522851
Moia LJ et al. Immunosuppressants and calcineurin inhibitors, cyclosporin A and FK506, reversibly inhibit epileptogenesis in amygdaloid kindled rat. 1994 Brain Res. pmid:7522929
Kattner A et al. Conversion from CyA to CyA-NOF in a cholestatic liver grafted patient with CyA malabsorption. 1994 Transplant. Proc. pmid:7524225
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
Tacrolimus introduced for use in liver transplantation. 1994 Am J Hosp Pharm pmid:7524317
Przepiorka D et al. Blood tacrolimus concentration unchanged by plasmapheresis. 1994 Am J Hosp Pharm pmid:7524318
Burnett D et al. Inhibition by FK506 of formyl peptide-induced neutrophil activation and associated protein synthesis. 1994 Biochem. Pharmacol. pmid:7524504
Rosenwirth B et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. 1994 Antimicrob. Agents Chemother. pmid:7527198
Shaw LM and Brayman KL FK-506 therapeutic drug monitoring. 1994 Clin. Chem. pmid:7527305
Winkler M et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. 1994 Clin. Chem. pmid:7527306
Lewis HM Therapeutic progress. II: Treatment of psoriasis. 1994 J Clin Pharm Ther pmid:7527403
Cheng JW et al. 15N NMR relaxation studies of the FK506 binding protein: dynamic effects of ligand binding and implications for calcineurin recognition. 1994 Biochemistry pmid:7512379
Chen SR et al. Asymmetrical blockade of the Ca2+ release channel (ryanodine receptor) by 12-kDa FK506 binding protein. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7527548
Mori A et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. 1994 Int. Arch. Allergy Immunol. pmid:7512393
Okubo Y et al. Cytokine production in patients with mite-sensitive bronchial asthma. 1994 Int. Arch. Allergy Immunol. pmid:7512395
Wilson JR et al. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. 1994 Muscle Nerve pmid:7512691
Lhoëst G et al. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. 1993 Sep-Oct Drug Metab. Dispos. pmid:7694828
Iwasaki K et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. 1993 Nov-Dec Drug Metab. Dispos. pmid:7507815
Fukuse T et al. Combined therapy with FK-506 and cyclosporine for canine lung allotransplantation: immunosuppressive effects and blood trough levels. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508750
Morris RE New small molecule immunosuppressants for transplantation: review of essential concepts. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508752
Schreier MH Immunophilins and immunosuppression. 1993 Mar-Apr Clin. Exp. Rheumatol. pmid:7686830
Piekoszewski W et al. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. 1993 Jul-Aug Drug Metab. Dispos. pmid:7690698
Kobayashi J et al. A new rat infection-heart transplant model: effect of infection on graft survival studies. 1993 Jul-Aug J. Heart Lung Transplant. pmid:7690253
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Klintmalm GB et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679840
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Jayaraman T and Marks AR Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. 1993 J. Biol. Chem. pmid:7503980
D'Ambrosio R et al. Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood. 1993 Ther Drug Monit pmid:7504339
Reese JC et al. The effect of FK506 on canine bile flow. 1993 Transplantation pmid:7504342
Valdivia LA et al. Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. 1993 Transplantation pmid:7681230
Fujimura A et al. Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. 1993 Jpn. J. Pharmacol. pmid:7681489
Nishinaka Y et al. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. 1993 J. Cardiovasc. Pharmacol. pmid:7681507
Mühl H et al. Cyclosporin derivatives inhibit interleukin 1 beta induction of nitric oxide synthase in renal mesangial cells. 1993 Eur. J. Pharmacol. pmid:7506668
Simek SL et al. Sequence and localization of a novel FK506-binding protein to mouse chromosome 11. 1993 Genomics pmid:7507077
Izumi S and Okuhara M [FK506 and kifunensine, new immunomodulators of microbial origin]. 1993 Tanpakushitsu Kakusan Koso pmid:7692469
Wakugami T et al. Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. 1993 Tohoku J. Exp. Med. pmid:7692621
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Sato M et al. FK506 inhibits phytohemagglutinin-, but not interferon-gamma-, induced HLA-DR antigen expression and accessory cell function on primary cultured human thyroid cells. 1993 Acta Endocrinol. pmid:7509103
Clipstone NA and Crabtree GR Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. 1993 Ann. N. Y. Acad. Sci. pmid:7509131
Blaehr H et al. Acute effects of FK506 and cyclosporine A on cultured human proximal tubular cells. 1993 Eur. J. Pharmacol. pmid:7683267
Kadmon M et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. 1993 Gastroenterology pmid:7683296
Denesyuk AI et al. Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. 1993 Biochem. Biophys. Res. Commun. pmid:7683466
Waschulewski IH et al. Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. 1993 Br. J. Pharmacol. pmid:7683567
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Takaya S et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. 1993 Transplant. Proc. pmid:7685953
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Yamaoka K et al. Cyclosporin A and FK506 block the negative signaling mediated by surface IgM cross-linking in normal human mature B cells. 1993 Immunol. Lett. pmid:7688712
Smith DF et al. Two FKBP-related proteins are associated with progesterone receptor complexes. 1993 J. Biol. Chem. pmid:7688746
Jacobs JC et al. Pyoderma gangrenosum in infancy. 1993 J. Am. Acad. Dermatol. pmid:7688775
Garrity GM et al. Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and rapamycin. 1993 J. Ind. Microbiol. pmid:7688970
Mollison KW et al. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7689812
Tai PK et al. P59 (FK506 binding protein 59) interaction with heat shock proteins is highly conserved and may involve proteins other than steroid receptors. 1993 Biochemistry pmid:7689858
Lieberman R FK506, artificial intelligence and pharmacoeconomics. 1993 J Clin Pharmacol pmid:7690045
McMichael J et al. An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. 1993 J Clin Pharmacol pmid:7690046
Armitage JM et al. Pediatric lung transplantation. The years 1985 to 1992 and the clinical trial of FK 506. 1993 J. Thorac. Cardiovasc. Surg. pmid:7679172
Ito K and Komatsu Y [Drug induced hemolytic uremic syndrome]. 1993 Nippon Rinsho pmid:7679450
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526